Provided by Tiger Trade Technology Pte. Ltd.

Incyte

123.28
-2.7300-2.17%
Post-market: 123.280.00000.00%19:34 EDT
Volume:1.46M
Turnover:181.20M
Market Cap:24.99B
PE:15.70
High:126.31
Open:125.09
Low:122.58
Close:126.01
52wk High:132.60
52wk Low:81.09
Shares:202.70M
Float Shares:169.82M
Volume Ratio:1.07
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(TTM):7.85
EPS(LYR):6.41
ROE:30.67%
ROA:16.83%
PB:3.94
PE(LYR):19.23

Loading ...

Incyte Completes USD 1.25 Billion Acquisition of Vega Therapeutics

Reuters
·
Jul 06

Press Release: Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding Its Hematology Portfolio

Dow Jones
·
Jul 06

Uk's MHRA Approves Retifanlimab for Treatment of Advanced Merkel Cell Skin Cancer

Reuters
·
Jul 06

Incyte Corp. Stock Underperforms Thursday When Compared to Competitors Despite Daily Gains

Dow Jones
·
Jul 03

US FDA Approves Orca Bio's Blood Cancer Therapy

Reuters
·
Jul 01

Incyte Corp. Stock Underperforms Tuesday When Compared to Competitors

Dow Jones
·
Jul 01

Incyte Price Target Maintained with a $140.00/share by HC Wainwright & Co.

Dow Jones
·
Jun 29

Barclays Keeps Their Buy Rating on Incyte (INCY)

TIPRANKS
·
Jun 29

Weekly Winners | Bio-Techne Soars 23%; AbbVie Surges 17%; United Airlines Jumps 15%; Corning, Merck Gain 13%

Tiger Newspress
·
Jun 28

Accenture, Estée Lauder, Luckin, Incyte, BILL Trending

TIPRANKS
·
Jun 27

Incyte Corp. Stock Rises 5.8%, Outperforms Peers

Dow Jones
·
Jun 27

Incyte is Maintained at Neutral by UBS

Dow Jones
·
Jun 27

Incyte Winds Down Itacitinib Rollover Study: What Investors Should Know

TIPRANKS
·
Jun 27

Movement Alert|Incyte Rises 5.84% in Regular Trading, Opzelura Receives Positive EU CHMP Opinion for Atopic Dermatitis

Market Focus
·
Jun 27

Incyte Shares Rise 5.2% After Co Announces Positive EU Regulatory Opinion for Opzelura Skin Disease Treatment

THOMSON REUTERS
·
Jun 26

Incyte to Present Phase 1/2 Vga039 Data in Von Willebrand Disease at ISTH Congress

Reuters
·
Jun 26

Incyte announces positive CHMP opinion of Opzelura Cream

TIPRANKS
·
Jun 26

Incyte Says EMA Panel Backs EU Approval of Opzelura Cream for Moderate Atopic Dermatitis in Adults

Reuters
·
Jun 26

Incyte Announces Positive Chmp Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis

THOMSON REUTERS
·
Jun 26

Incyte (INCY) Lands Fresh Clinical Wins, Is It Fully Valued?

Simply Wall St.
·
Jun 26